French biotech firm surprises analysts with corona vaccine data
French biotech company Valneva has surprised the market with positive Covid-19 vaccine data, something one analyst welcomes, as different types of boosters may be necessary in the ongoing fight against the virus.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
After a rollercoaster year, French biotech business Valneva is experiencing somewhat of a comeback on the Covid-19 front, after having presented promising phase III data for its Covid-19 vaccine. Investors have rewarded it by sending Valneva stock up by more than 30 percent.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA approves Pfizer and Moderna Covid-19 booster shots
For subscribers
Danish government cancels vaccine production tender
For subscribers
.jpg&w=384&q=75)
